View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
April 8, 2020

Lamellar Biomedical turns its Lamellasome tech to Covid-19

By Chloe Kent

Glasgow-based Lamellar Biomedical has announced the launch of a programme to address the potentially fatal consequences of Covid-19 on respiratory function via its Lamellasome platform.

Lamellasome therapeutics are synthetic anionic lipid vesicles composed of proprietary blends of lipids based on naturally occurring human lamellar bodies. They are synthetically formulated and can be manufactured using standard, scalable industry processes and components, and are ingested through inhalation via nebuliser.

A Lamellasome treatment used in the early stages of a Covid-19 infection could reduce the inflammatory response of acute respiratory distress syndrome (ARDS) seen in patients. In a large animal in‑vivo model of radiation-induced lung injury, inhaled Lamellasome protected lung cells and tissues from injury, pneumonitis and fibrosis at the capillary membrane.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network